Search the Newsreel

Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares

Halozyme (NASDAQ: HALO) President and CEO Helen Torley exercised stock options and sold 60,000 common shares between August 17-19, 2026, under a pre-arranged Rule 10b5-1 trading plan. She exercised options at $18.41 per share and sold the shares in the high $90s to approximately …

Kratos Defense & Security Solutions president Carrai sells $1.67m in shares

Phillip D. Carrai, President of the STC Division at Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS), recently sold 26,500 shares of company stock totaling approximately $1.67 million. These transactions, which occurred on August 17, 2026, were executed both under a pre-arranged 10b5-1 trading plan …

Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN

Handelsbanken Fonder AB recently acquired 53,200 shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) valued at approximately $1.18 million, contributing to institutional investors owning 96.68% of the company. Analysts maintain a "Moderate Buy" rating with a consensus target price of $34.42, despite the company reporting a …

Broadridge Financial Solutions Inc (BR) Shares Surge 3.6% -- What GF Score of 80 Tells Investors

Broadridge Financial Solutions Inc (BR) shares surged 3.6% to $176.03, despite being down 31.7% year-over-year. The company is considered "Modestly Undervalued" with a GF Value™ of $246.29 and boasts a strong GF Score™ of 80/100, indicating robust fundamentals, particularly in profitability and growth. However, …

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance1: Double-digit revenue growth and gross …

Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics CFO Louis Edward Tamayo sold 4,117 shares of LXEO stock for $20,214.47 to cover tax obligations, reducing his stake by 4.24% to 92,907 shares. The company's stock rose to $5.37 during mid-day trading despite missing quarterly EPS estimates, and institutional ownership stands …

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock

Major shareholder Group Walters purchased 4,335,000 shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock for $15.17 million, increasing their position by 32.09% to 17.84 million shares. This transaction occurred on August 14th, with the stock bought at an average price of $3.50 per share. Despite the …

An2 Therapeutics director Robin Readnour sells $212,701 in common stock By Investing.com

Robin Shane Readnour, a director at AN2 Therapeutics (ANTX), sold 35,402 shares of common stock for a total of $212,701 on August 17, 2026. These transactions, executed at an average price of $6.0082 per share, were conducted under Rule 10b5-1 trading plans. Despite the …

Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Jolanda Howe, SVP of Mirum Pharmaceuticals (NASDAQ:MIRM), sold 40,000 shares of the company's stock for $4 million on August 18th, reducing her stake by 96.91% to 1,274 shares. This sale follows several other transactions since June. The company's stock trades at $102.24 with a …

Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX

This article focuses on the total non-current assets of Definium Therapeutics, Inc. (NASDAQ: DFTX). It appears to be a financial data page from TradingView, displaying company information and navigational elements for financial analysis. The content indicates market data and reference data providers for the …

Enterprise value to EBITDA forward of Context Therapeutics Inc. – NASDAQ:CNTX

This article displays the Enterprise Value to EBITDA forward for Context Therapeutics Inc. (NASDAQ: CNTX). It provides basic financial information related to the company within the TradingView platform. The content is primarily a data point display from a financial charting service.

Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest Session - Analyst Coverage Count

We're Not Very Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Rate

BioCryst (BCRX) Quarterly Figures: Reported EPS Tops Expectations in the Latest Reading; Price Reaction: The Share Price Adds 3.81% at the Close - Earnings Growth Analysis

Marie Mendoza Sells 1,513 Shares of Kratos Defense & Security Solutions (NASDAQ:KTOS) Stock

Beam (BEAM) Latest Quarter: EPS Falls Short of Its Estimate on the Day; Post-Earnings: The Stock Gains 9.41% in the Current Update - Revenue Inflection Point

TEVA Stock Quote Price and Forecast

PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,813 Shares of Stock

PTC Therapeutics VP Mark Elliott Boulding sold 2,813 shares of the company's stock on August 17th for a total of $204,139.41, reducing his ownership by 2.60%. This sale was part of a pre-arranged Rule 10b5-1 trading plan and follows earlier sales in June and …

Sonoma Pharmaceuticals cancels special meeting due to lack of quorum By Investing.com

Sonoma Pharmaceuticals announced the cancellation of its adjourned special meeting of stockholders due to a lack of quorum, as not enough shareholders participated to meet the required threshold. The meeting was originally called to address matters detailed in a proxy statement from May 2026. …

Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock By Investing.com

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alesta Therapeutics, a clinical-stage biotech company. According to a company press release, BioMarin will pay …

Rigetti Computing Establishes Dedicated Systems Delivery Organization to Scale Customer Deployments and Advance Quantum Processor Roadmap

Rigetti Computing, Inc. David Rivas appointed to newly created Chief Operating Officer role; Andrew Bestwick, Ph.D. appointed Chief Technology Officer BERKELEY, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) ("Rigetti"), a pioneer in full-stack quantum computing, today announced a new …

AARD Class Action Reminder - Robbins LLP Reminds Investors

Robbins LLP is reminding investors of a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) concerning its IPO in February 2025 and subsequent stock drop. The lawsuit alleges that Aardvark misled investors about the safety and efficacy of its lead drug candidate, ARD-101, …

Nearly one-fifth of Zentalis (NASDAQ: ZNTL) sits with one investor group

An amended Schedule 13G/A filing reveals that The Walters Group, associated with William T. Walters and Susan B. Walters, holds 18.8% of Zentalis Pharmaceuticals (NASDAQ: ZNTL) common stock. This significant ownership amounts to 17,844,973 shares out of 94,668,568 shares outstanding. The group reports shared …

Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock

Walters Group, a 10% owner and director of Zentalis Pharmaceuticals Inc., acquired 4,335,000 shares of the company's common stock for $15.17 million at $3.50 per share. This transaction increases their total beneficial ownership to 17,844,973 shares, despite a recent decline in the stock, which …

Atea (AVIR) Q2 2026 Earnings Call Transcript

MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs

MapLight Therapeutics, Inc. (MPLT) reported that its CEO, Christopher A. Kroeger, received equity awards on August 17, 2026, including an option to purchase 93,955 shares of voting common stock and 23,145 restricted stock units (RSUs). These awards have specific vesting schedules tied to continued …

MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs

MapLight Therapeutics, Inc. (MPLT) reported that Chief Discovery Officer Anatol Kreitzer received equity awards on August 17, 2026. These awards include an option to purchase 24,455 shares of common stock at an exercise price of $11.245 per share, and 6,020 restricted stock units (RSUs), …

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

The Rosen Law Firm is encouraging investors of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to secure counsel before the October 5, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the expected …

Ninth Circuit Revives Regeneron Kickback Whistleblower Lawsuit

A federal appeals court has partially revived a whistleblower lawsuit against Regeneron Pharmaceuticals Inc., alleging illegal kickbacks to physicians for prescribing its drugs. The Ninth Circuit Court of Appeals reversed a lower court's dismissal of the Anti-Kickback Statute claims under the False Claims Act, …

Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules

Aurinia Pharmaceuticals Inc. and its subsidiary, Aurinia Pharma U.S., Inc., have reached a settlement agreement with Teva Pharmaceuticals Inc. concerning patent infringement litigation. The dispute was related to Teva's Abbreviated New Drug Application (ANDA) for generic 7.9 mg voclosporin oral capsules. The settlement was …

ETFs Investing in United Therapeutics Corporation Stocks

This article lists Exchange Traded Funds (ETFs) that hold stocks of United Therapeutics Corporation (UTHR), providing detailed information for each fund such as market value, weight of UTHR stock, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year …

Jorey Chernett (NASDAQ: KZIA) reports multi-million ADS stake

Investor Jorey Chernett has filed an amended Schedule 13G/A, disclosing beneficial ownership of 2,339,009 American Depositary Shares (ADS) of KAZIA THERAPEUTICS LTD (NASDAQ: KZIA). This stake represents 19.6% of the company's outstanding ADS as of August 19, 2026. Chernett reports having sole voting and …

Mirum Pharmaceuticals SVP, Global Controller Sold Shares Worth Over $4M

Mirum Pharmaceuticals' SVP, Global Controller, Howe Jolanda, sold 40,000 shares of Common Stock for a total of $4,000,000 at $100.00 per share. Following this transaction, Jolanda directly owns 1,274 shares. This information is based on an SEC Form 4 filing and highlights an insider …

BioMarin to acquire Alesta Therapeutics for up to $490 million

BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Alesta Therapeutics for up to $490 million. The acquisition involves an upfront cash payment of $275 million for Alesta's lead asset, ALE1, a therapy for hypophosphatasia, with potential additional milestone payments of up to …

BIOMARIN PHARMACEUTICAL INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $98

BMO has initiated coverage on BioMarin Pharmaceutical Inc. (BMRN.O) with an "Outperform" rating. The firm has set a price target of $98 for the biotechnology company. This information was reported by Reuters.